Obesity Clinical Trial
Verified date | May 2006 |
Source | Aga Khan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Pakistan: Pakistan Medical Research Council |
Study type | Interventional |
Studies have established that high blood pressure (BP) is the most common risk factor for
cardiovascular disease (CVD). Despite a heavy burden of hypertension (33% of all persons
aged 45 years and over), there are no reliable data on comparative strategies to manage
hypertension in Pakistan. Our Wellcome Trust funded pilot study in Karachi, Pakistan on 320
adults aged 40 years and over showed that the prevalence of hypertension (95% CI) was 40.3%
(34.9-45.7%), and CVD was 32.5% (27.6-37.8%).
We will now conduct a study with two components: 1) cross sectional study to determine the
prevalence of CVD, and its determinants in Karachi, Pakistan; and 2) prospective, 2x2
factorial design, cluster allocation intervention study to evaluate the impact of a i)
Population approach of household health education (HHE) by community health workers (CHW) on
BP levels of population aged 5 years or over in low-middle income communities of Karachi;
and ii) High-Risk approach of special BP management administered by intensively trained
local general practitioners on BP levels of hypertensive subjects aged > = 40 years from the
above population.
The cost effective BP control strategy would serve as a model for a much-needed national
level hypertension control programme in Pakistan, and possibly other developing countries in
South Asia.
We hypothesize that 1) HHE delivered by trained CHW is superior to no HHE in lowering BP
levels of the population; and 2) management of hypertension by specially trained GPs is
better than usual care provided in the communities of Karachi in lowering blood pressure of
hypertensive subjects.
Status | Active, not recruiting |
Enrollment | 0 |
Est. completion date | September 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 5 Years and older |
Eligibility |
Inclusion Criteria: - All subjects aged 5 years or over residing in randomly selected communities Exclusion Criteria: - Those who have severe co-morbid conditions - Pregnancy - Unable to give informed consent |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Pakistan | Aga Khan University | Karachi | Sind |
Lead Sponsor | Collaborator |
---|---|
Aga Khan University | Imperial College London, Wellcome Trust |
Pakistan,
Jafar TH, Jafary FH, Jessani S, Chaturvedi N. Heart disease epidemic in Pakistan: women and men at equal risk. Am Heart J. 2005 Aug;150(2):221-6. — View Citation
Jafar TH, Levey AS, Jafary FH, White F, Gul A, Rahbar MH, Khan AQ, Hattersley A, Schmid CH, Chaturvedi N. Ethnic subgroup differences in hypertension in Pakistan. J Hypertens. 2003 May;21(5):905-12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cross sectional: The prevalence (95% confidence intervals) of CVD, hypertension, diabetes, albuminuria, and mean values of lipid. | |||
Primary | Intervention study: Changes in systolic and diastolic BP, | |||
Primary | b) body mass index (BMI), e) waist hip ratio, and f) tobacco use from baseline to 2 year follow up visit | |||
Primary | Cost Outcome Measures: These will be computed for hypertensive adults. | |||
Primary | Primary outcomes: incremental cost per mm reduction in SBP, and DBP for each of the three intervention arms. | |||
Primary | the three intervention arms | |||
Secondary | Secondary Effect Outcomes: a) Proportion of subjects with mean follow-up BP less than 140/90 mm Hg, | |||
Secondary | and changes in b) BMI, c) waist hip ratio, and f) tobacco use. | |||
Secondary | Cost outcomes: the total cost per intervention and cost per subjects |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |